Serial Changes in von Willebrand Factor-Cleaving Protease (ADAMTS13) and Prognosis After Acute Myocardial Infarction - 16/08/11
, Kenji Soejima, PhD b, Shunichiro Fuchigami, MD a, Yoshinori Nakamura, MD c, Tsuyoshi Honda, MD a, Kenichi Tsujita, MD a, Yasuhiro Nagayoshi, MD a, Sunao Kojima, MD a, Hideki Shimomura, MD c, Seigo Sugiyama, MD a, Kazuteru Fujimoto, MD d, Michihiro Yoshimura, MD a, Tomohiro Nakagaki, PhD b, Hisao Ogawa, MD a
Corresponding author: Tel: 81-96-373-5175; fax: 81-96-362-3256.Résumé |
Von Willebrand factor (VWF), a cofactor in platelet adhesion and aggregation, increases hemostasis and thrombosis. Recently, a metalloprotease that cleaves VWF multimers has been identified, namely ADAMTS13. The aim of this study was to investigate the relation between serial changes in plasma VWF and ADAMTS13 and the prognosis after acute myocardial infarction (AMI). We measured serial changes of plasma VWF and ADAMTS13 antigen levels in 92 patients with AMI and 40 control subjects. VWF levels were significantly higher in patients with AMI compared with controls (p <0.01) on admission, peaked 3 days after admission, and remained high for 14 days. In contrast, on admission, ADAMTS13 levels were significantly lower in patients with AMI compared with controls (p <0.0001), with minimum antigen levels reached after 3 days, and remained lower for 14 days. The ratio of VWF/ADAMTS13 antigen levels was higher in patients with AMI compared with controls throughout the time course. Cox hazards analysis revealed that the early increase of VWF and VWF/ADAMTS13 ratio levels and the early decrease of ADAMTS13 levels were significant predictors of future thrombotic events during the 1-year follow-up period. Kaplan-Meier analysis demonstrated that patients with major decreases of ADAMTS13 levels and high increases of VWF/ADAMTS13 levels had significantly greater probabilities for development of thrombotic events (p = 0.0104 and 0.0209, respectively). In conclusion, these findings suggest that monitoring the changes of VWF and ADAMTS13 antigen levels in the early phase might be valuable for predicting and preventing thrombosis during 1-year follow-up in patients with AMI.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported in part by Grants-in-Aid for Scientific Research B17390232 and C17590752 from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan. |
Vol 100 - N° 5
P. 758-763 - septembre 2007 Retour au numéro
Article précédent
- Relation of C-Reactive Protein and New-Onset Atrial Fibrillation in Patients With Acute Myocardial Infarction
- Doron Aronson, Monther Boulos, Abeer Suleiman, Salma Bidoosi, Yoram Agmon, Michael Kapeliovich, Rafael Beyar, Walter Markiewicz, Haim Hammerman, Mahmoud Suleiman
- Usefulness of Detectable Levels of Troponin, Below the 99th Percentile of the Normal Range, as a Clue to the Presence of Underlying Coronary Artery Disease
- Olaf Schulz, Claudia Paul-Walter, Matthias Lehmann, Klaus Abraham, Gunnar Berghöfer, Ingolf Schimke, Allan S. Jaffe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?